中国临床医学2026，Vol.33Issue(3)：533-543,11.DOI:10.12025/j.issn.1008-6358.2026.20251026
PD-L1与TGF-β协同调控肿瘤免疫逃逸:机制与双靶向治疗进展
PD-L1 and TGF-β cooperatively regulate tumor immune escape:mechanisms and advances in dual-targeting therapy
摘要
Abstract
While programmed cell death ligand 1(PD-L1)inhibitors have yielded breakthroughs in tumor therapy,their efficacy is constrained by the heterogeneity of the tumor microenvironment and multiple immunosuppressive pathways.In recent years,research has revealed that transforming growth factor-β(TGF-β)synergistically drives tumor cell immune escape with PD-L1 via pathways such as metabolic reprogramming,epithelial-mesenchymal transition,and SOX family factors.Currently,various PD-L1/TGF-β bispecific antibodies(bsAbs)have exhibited promising therapeutic potential in early-phase clinical trials,yet they still confront challenges related to toxicity and drug resistance.This article systematically reviews the mechanisms by which PD-L1 and TGF-β synergistically regulate tumor immune escape,summarizes the clinical research progress of bsAbs,and discusses strategies for novel drug design and biomarker development,with the aim of offering new insights for the development of combined tumor immunotherapy strategies.关键词
PD-L1/TGF-β/双特异性抗体/代谢重编程/上皮-间质转化/免疫逃逸Key words
programmed cell death ligand 1/transforming growth factor-β/bispecific antibody/metabolic reprogramming/epithelial-mesenchymal transition/immune escape分类
医药卫生引用本文复制引用
何倩倩,杨艳丽,张晗,陈哲宇,姬菩忠..PD-L1与TGF-β协同调控肿瘤免疫逃逸:机制与双靶向治疗进展[J].中国临床医学,2026,33(3):533-543,11.基金项目
甘肃省卫生健康行业科研项目(GSWSKY2024-59),甘肃省科技计划资助项目(22JR5RA022).Supported by Scientific Research Project of Gansu Provincial Health Industry(GSWSKY2024-59)and Gansu Provincial Science and Technology Program Funding Project(22JR5RA022). （GSWSKY2024-59）
